Lonnie Moulder, Zenas BioPharma CEO

Lon­nie Moul­der's Zenas clos­es a $200M Se­ries C to broad­en lead drug's au­toim­mune po­ten­tial

Lon­nie Moul­der’s lat­est biotech has se­cured some new cash to ex­pand its work in au­toim­mune dis­eases.

The start­up, Zenas Bio­Phar­ma, closed a $200 mil­lion Se­ries …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.